This site is intended for healthcare professionals
Abstract digital waveforms in blue and purple
FDA Drug information

Deferasirox

Read time: 1 mins
Marketing start date: 23 Nov 2024
...
 

Summary of product characteristics


Effective Time

20230921

Version

5

Spl Product Data Elements

deferasirox deferasirox DEFERASIROX DEFERASIROX CROSCARMELLOSE SODIUM HYPROMELLOSE 2910 (6 MPA.S) MAGNESIUM STEARATE MICROCRYSTALLINE CELLULOSE POLOXAMER 407 POLYETHYLENE GLYCOL 8000 POVIDONE K30 SILICON DIOXIDE TALC TITANIUM DIOXIDE off-white 1275 deferasirox deferasirox DEFERASIROX DEFERASIROX CROSCARMELLOSE SODIUM D&C RED NO. 27 FD&C BLUE NO. 2 HYPROMELLOSE 2910 (6 MPA.S) MAGNESIUM STEARATE MICROCRYSTALLINE CELLULOSE POLOXAMER 407 POLYETHYLENE GLYCOL 8000 POVIDONE K30 SILICON DIOXIDE TALC TITANIUM DIOXIDE 1277 deferasirox deferasirox DEFERASIROX DEFERASIROX CROSCARMELLOSE SODIUM FD&C BLUE NO. 2 FERRIC OXIDE YELLOW HYPROMELLOSE 2910 (6 MPA.S) MAGNESIUM STEARATE MICROCRYSTALLINE CELLULOSE POLOXAMER 407 POLYETHYLENE GLYCOL 8000 POVIDONE K30 SILICON DIOXIDE TALC TITANIUM DIOXIDE light blue 1276

Application Number

ANDA211383

Brand Name

Deferasirox

Generic Name

deferasirox

Product Ndc

70771-1472

Product Type

HUMAN PRESCRIPTION DRUG

Route

ORAL

Package Label Principal Display Panel

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL NDC 70771-1471-3 Deferasirox tablets, 90 mg 30 Tablets Rx only NDC 70771-1472-3 Deferasirox tablets, 180 mg 30 Tablets Rx only NDC 70771-1473-3 Deferasirox tablets, 360 mg 30 Tablets Rx only Deferasirox tablets image Deferasirox tablets

Drug section

CME banner

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Disclaimer

The drug Prescribing Information (PI), including indications, contra-indications, interactions, etc, has been developed using the U.S. Food & Drug Administration (FDA) as a source (www.fda.gov).

Medthority offers the whole library of PI documents from the FDA. Medthority will not be held liable for explicit or implicit errors, or missing data.

Drugs appearing in this section are approved by the FDA. For regions outside of the United States, this content is for informational purposes only and may not be aligned with local regulatory approvals or guidance.